Unknown

Dataset Information

0

Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review.


ABSTRACT: Glioblastoma (GBM) is the most common malignant tumor arising from brain parenchyma. Although many efforts have been made to develop therapies for GBM, the prognosis still remains poor, mainly because of the difficulty in total resection of the tumor mass from brain tissue and the resistance of the residual tumor against standard chemoradiotherapy. Therefore, novel adjuvant therapies are urgently needed. Recent genome-wide analyses of GBM cases have clarified molecular signaling mechanisms underlying GBM biology. However, results of clinical trials targeting phosphorylation-mediated signaling have been unsatisfactory to date. Protein phosphatases are enzymes that antagonize phosphorylation signaling by dephosphorylating phosphorylated signaling molecules. Recently, the critical roles of phosphatases in the regulation of oncogenic signaling in malignant tumor cells have been reported, and tumorigenic roles of deregulated phosphatases have been demonstrated in GBM. However, a detailed mechanism underlying phosphatase-mediated signaling transduction in the regulation of GBM has not been elucidated, and such information is necessary to apply phosphatases as a therapeutic target for GBM. This review highlights and summarizes the phosphatases that have crucial roles in the regulation of oncogenic signaling in GBM cells.

SUBMITTER: Tomiyama A 

PROVIDER: S-EPMC6406705 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review.

Tomiyama Arata A   Kobayashi Tatsuya T   Mori Kentaro K   Ichimura Koichi K  

Cancers 20190219 2


Glioblastoma (GBM) is the most common malignant tumor arising from brain parenchyma. Although many efforts have been made to develop therapies for GBM, the prognosis still remains poor, mainly because of the difficulty in total resection of the tumor mass from brain tissue and the resistance of the residual tumor against standard chemoradiotherapy. Therefore, novel adjuvant therapies are urgently needed. Recent genome-wide analyses of GBM cases have clarified molecular signaling mechanisms under  ...[more]

Similar Datasets

| S-EPMC8625235 | biostudies-literature
| S-EPMC8175629 | biostudies-literature
| S-EPMC1255782 | biostudies-literature
| S-EPMC5522122 | biostudies-other
| S-EPMC2994645 | biostudies-literature
| S-EPMC10963412 | biostudies-literature
| S-EPMC4931820 | biostudies-literature
| S-EPMC1431701 | biostudies-literature
| S-EPMC7049744 | biostudies-literature
| S-EPMC6444631 | biostudies-literature